What Precise Bio does

Precise Bio is a clinical-stage regenerative medicine company developing and commercializing 4D bio-fabricated functional tissues and organs, with a primary focus on ophthalmological applications. The company's lead product, PB-001, is the world's first 3D bio-printed corneal implant manufactured from cultured human corneal cells rather than donor tissue, directly addressing the global shortage of donor corneas. The proprietary bio-fabrication platform enables repeatable, scalable production of lab-grown tissue implants designed to reduce reliance on human donors and mitigate rejection risks associated with traditional donor tissue.

PB-001 is currently being evaluated in a Phase 1 clinical trial at Rambam Medical Center in Haifa, Israel, under authorization from Israel's Ministry of Health. Three patients have been successfully transplanted to date, with the first patient, who was blind, experiencing dramatic vision restoration and no serious adverse events reported across the procedures. The company plans to enroll approximately 10 to 15 patients total, with topline results expected in Q4 2026. Precise Bio has received support from the Israel Innovation Authority as part of Israel's National Bioconvergence Program.

The company's business model is structured around eventual commercialization of bio-printed corneal implants to healthcare providers, hospitals, and ophthalmology centers upon regulatory approval, following a traditional medical device and pharmaceutical pathway. The company is privately held and venture-backed, having raised approximately $27.5 million across disclosed funding rounds including a $12 million round led by Carl Zeiss Meditec. Revenue generation is contingent on successful clinical trial outcomes and subsequent regulatory clearances in target markets, with the broader corneal implants market projected to reach $2.01 billion by 2030.

Name

Precise Bio

Legal name

Precise Bio, Inc.

Website

https://precise-bio.com

Company type

Private

Founded year

2015

Operating status

Operating

Headcount range

11–50 employees

Short description

Precise Bio is a clinical-stage regenerative medicine company developing 3D bio-printed corneal implants via its proprietary bio-fabrication platform. Its lead product PB-001, designed to address donor cornea shortages, is currently in Phase 1 clinical trials in Israel.

Ownership category

akta.pro rank

Product category

Regenerative Medicine — Ophthalmic Medical Devices

NAICS

Surgical Appliance and Supplies Manufacturing (339113), Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Cornea & External Disease Surgical Devices (Keratoplasty Tools, Cross-Linking Systems, Amniotic Membrane Delivery) (HLAHAJAK)

akta.pro secondary industries

Bioprinting & Biofabrication Systems (Tissue/Cell Printing Hardware) (IMAAAAAG), 3D-Printed & Patient-Specific Implants (Custom Ortho/Spine/Cranial) (HLAHAEAJ)

Keywords

• 3D bio-printed corneas
• Regenerative ophthalmology
• Bio-fabricated tissue implants
• Cultured corneal cells
• Ophthalmic medical devices

Headquarters

HQ city

Winston Salem

HQ country

United States

HQ region

North America

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales

Revenue model

1. 3D-Bio-Printed Corneal Implants: Once regulatory approvals are obtained, the company expects to generate revenue from the sale of its 3D-bio-printed corneal implants (PB-001) to healthcare providers and hospitals for corneal transplant procedures.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels2 records

Core offering

Precise Bio is a clinical-stage regenerative medicine company that develops and commercializes 4D bio-fabricated functional tissues and organs, with its lead product being PB-001, the world's first 3D bio-printed corneal implant made from cultured human corneal cells. The implant is currently in Phase 1 clinical trials in Israel to restore vision in patients suffering from corneal blindness. The proprietary bio-fabrication platform enables scalable manufacturing of lab-grown corneal implants to address the global shortage of donor corneas.

Product overview

Precise Bio is a clinical-stage regenerative medicine company specializing in bio-printed tissues with a focus on ophthalmology. The company's primary product is PB-001, the world's first 3D-bio-printed corneal implant, which has entered human clinical trials. The technology utilizes a proprietary bio-fabrication platform that manufactures implants from cultured human corneal cells. This platform enables the production of lab-grown tissue implants to address donor shortages and expand access to corneal transplants.

Differentiator

Problem solved

Functional benefit

Brands

• PB-001: The world's first bio-printed corneal implant to enter human clinical trials, developed using Precise Bio's bio-fabrication platform from cultured human corneal cells.

Products and services

• PB-001 3D Bio-Printed Corneal Implant The world's first 3D bio-printed corneal implant, manufactured from cultured human corneal cells using Precise Bio's proprietary bio-fabrication platform. Currently in Phase 1 clinical trials to restore vision in patients with corneal blindness or severe vision impairment, addressing the global shortage of donor corneas.

Quantifiable outcome

• First patient who was blind experienced dramatic vision restoration following PB-001 transplant
• +1 more outcomes

Named customers1 record

Segments2 records

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature2 records

Partnerships

Two partnerships are on record, tiered core.

• Rambam Medical CentercoreStrategic or Co-development Partner · 23 February 2026Primary clinical trial site for Phase 1 study of PB-001 3D-bio-printed corneal implant. Medical center in Haifa, Israel received authorization from Israel's Ministry of Health to conduct the transplant procedures. The first patient, who was blind, experienced dramatic vision restoration following the procedure.
• Israel Ministry of HealthcoreOthersRegulatory authority that authorized advancement of Phase 1 clinical trial and provided oversight for the 3D-bio-printed corneal implant transplantation procedures.

Scale indicators4 records

Recent moves6 records

Expansion highlights5 records

Broad incumbents

• Carl Zeiss Meditec: Global leader in ophthalmic surgical devices and diagnostics. Carl Zeiss Meditec led Precise Bio's $12M funding round and is a strategic investor validating the corneal implant thesis. Comparable as both an incumbent ophthalmic franchise and a key commercial partner candidate.
• Organogenesis: Commercial-stage regenerative medicine company marketing bioengineered skin and wound care products. Comparable as a broader regenerative medicine incumbent demonstrating the commercial viability of cell-based tissue products and a potential acquirer or strategic partner for Precise Bio.
• 3D Systems: Major 3D printing company with a healthcare division producing patient-specific surgical models, implants, and bioprinting research collaborations. Comparable as a broad incumbent in 3D printing healthcare applications and a potential partner or acquirer for bioprinting assets like Precise Bio.

Direct peers

• CorneaGen: Leading provider of donor corneal tissue for transplantation in the US. Directly comparable as it serves the same patient population (corneal blindness) that Precise Bio targets with PB-001, and is the incumbent whose supply scarcity Precise Bio's bio-printed alternative is designed to displace.
• TissueTech: Regenerative medicine company focused on ocular surface diseases using placental tissue technology. Comparable as a clinical/commercial regenerative ophthalmology peer addressing corneal and ocular surface conditions, overlapping with Precise Bio's target indications.
• Aspect Biosystems: Bioprinting platform company developing 3D-printed tissue therapeutics, with programs in metabolic disease and ophthalmology. Comparable as a direct peer in the 3D bioprinting of human tissues space, pursuing similar regenerative medicine outcomes through a different pipeline.
• BICO (CELLINK): Bioprinting-focused life sciences company providing bioinks, 3D bioprinters, and tissue engineering services. Comparable as a peer in the 3D bioprinting tools and tissue fabrication space that supplies and partners with regenerative medicine developers including those in ophthalmology.
• CorNeat Vision: Israeli ophthalmic implant developer with a synthetic corneal implant (CorNeat KPro) that has entered human clinical use. Comparable as a direct competitor in the corneal restoration space, offering a non-biological alternative to Precise Bio's bio-printed PB-001 implant.

Emerging players

• Vericel: Commercial-stage cell therapy company developing autologous and allogeneic cellular products for cartilage repair and burn treatment. Comparable as a clinical-to-commercial cell therapy peer providing insight into regulatory pathway and capital requirements for advanced tissue products.
• MiMedx: Regenerative medicine company commercializing placental tissue allografts for wound care and surgical recovery. Comparable as a peer in the regenerative tissue products space addressing surgical applications with a more advanced commercial stage than Precise Bio.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds3 records

Investors3 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Precise Bio